Attention: open in a new window. E-mailPrintPDF
The management board pharma group Selvita announced that, in line with the clinical trial schedule, its drug in development SEL120 is to be administered to the first patient to treat…

Order subscription to read this article




Order at
Order from our partners:

Call us:

Find us: